Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
11:15am, Monday, 04'th May 2026
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) shares are up on Monday following the announcement that the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational trea
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with PSC on May 4, 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
09:45am, Sunday, 19'th Apr 2026
Vertex Pharmaceuticals has shown steady financial growth. Mirum Pharmaceuticals is getting closer to being profitable.
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
12:41pm, Friday, 17'th Apr 2026
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 13'th Apr 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Prediction: Buying This Biotech Stock Today Could Set You Up for Life
05:43am, Monday, 13'th Apr 2026
Mirum Pharmaceuticals already markets three therapies. The company plans to report four pivotal readouts from clinical studies over the next 18 months.
Egetis Appoints Tiago Nunes as Chief Medical Officer
01:15am, Thursday, 09'th Apr 2026
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Office
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC
05:07am, Tuesday, 07'th Apr 2026
SG Americas Securities LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commiss
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Moderate Buy” from Analysts
04:08am, Saturday, 04'th Apr 2026
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings repo
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
09:10am, Wednesday, 01'st Apr 2026
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
12:31pm, Friday, 27'th Mar 2026
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $3,769,800.30 in Stock
04:26am, Friday, 20'th Mar 2026
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 40,985 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an averag
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
12:40pm, Tuesday, 17'th Mar 2026
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
